The U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments

This report examines the current and future market potential of the U.S. market for biodefense-related rapid pathogen identification and treatments. It offers a detailed analysis of the competitive environment, regulatory scenario, technological development, drivers and restraints, and identifies opportunities and trends in market growth.

The report provides an overview of the U.S. market for biodefense-related rapid pathogen identification and treatments and analyzes market trends. It includes global revenue ($ million) for the base year 2025 and estimated data for the forecast period 2026 to 2031. Based on type, the market is segmented into detection devices, sensors, and therapeutics. The detection devices segment is further segmented based on testing method and device type. The report also focuses on segmentation based on application and end user. The application segmentation includes detection and diagnosis, prevention, and treatment.

By end user, the market is segmented into academic and research institutes, government and defense agencies, hospitals, and pharma and biotechnology companies. The report focuses on the major emerging technologies that affect the market and vendor landscape. It also has a dedicated section of company profiles that covers details of leading key companies.

The report includes:

28 data tables and 51 additional tables
An overview and analysis of the U.S. market for biodefense-related rapid pathogen identification and treatments
Analyses of market trends, with revenue data for 2023-2025, estimates for 2026, and forecasts through 2031
Market segmentation analysis by type, including detection devices and sensors
Market breakdown by application, including detection and diagnosis, prevention, and treatment
Market analysis by end user, including academic and research institutes, government and defense agencies, hospitals, and pharma and biotechnology companies
Facts and figures related to market dynamics, including key drivers, restraints, and opportunities
Insights derived from Porter’s Five Forces analysis
Discussion of emerging technologies, recent developments, and patent activity
Analysis of the competitive landscape, including industry structure and company share analysis
Company profiles of the leading players, including Thermo Fisher Scientific Inc., Biomerieux, F. Hoffmann-La Roche Ltd., Abbott, and OraSure Technologies Inc.

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Conclusion

Chapter 2 Market Overview

Overview
Delivery and Detection
Methods of Dissemination
Rapid Identification Products
Treatment
Vaccines
Antibiotics
Antimicrobial Resistance
Porter’s Five Forces Analysis
Threat of New Entrants (Moderate)
Bargaining Power of Suppliers (Low to Moderate)
Bargaining Power of Buyers (High)
Threat of Substitute Products (Low)
Industry Rivalry (High)
Macroeconomic Factor Analysis
U.S. Tariffs
Increasing Healthcare Expenditures
Geopolitical Factors

Chapter 3 Market Dynamics

Market Dynamics
Market Drivers
High Federal Funding and Biodefense Investments
Increasing Need for Infectious Disease Detection and Outbreak Surveillance
Increased Emergency Use Authorizations and Product Approvals
Market Restraints
High Equipment and Testing Costs
Lack of Awareness and Underdiagnosis of Infectious Conditions
Regulatory Barriers
Market Opportunities
Pathogen-Agnostic Detection Approaches
Point-of-Care Testing
Self-Testing Kits for Pathogen Detection

Chapter 4 Regulatory Landscape

U.S. Regulatory Aspects of Pathogen Identification Devices
U.S. Regulatory Aspects of Therapeutics for Pathogenic Conditions

Chapter 5 Emerging Technologies

Key Takeaways
Emerging Technologies
Multiplex PCR Syndromic Testing
AI-Based Biodefense Surveillance
Messenger RNA (mRNA) Vaccines
CRISPR-Based Diagnostics
Lab-on-a-Chip Systems for Public Health Monitoring

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Market Analysis by Type
Key Takeaways
Detection Devices
Sensors
Therapeutics
Market Analysis by Application
Key Takeaways
Detection and Diagnosis
Prevention
Treatment
Market Analysis by End User
Key Takeaways
Government and Defense Agencies
Hospitals
Pharmaceutical and Biotechnology Companies
Academic and Research Institutions

Chapter 7 Competitive Intelligence

Key Takeaways
Industry Structure
Competitive Analysis of U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments
Strategic Analysis

Chapter 8 Appendix

Methodology
Sources
Abbreviations

Company Profiles

ABBOTT
AGILENT TECHNOLOGIES INC.
BD
BIOMERIEUX
BIO-RAD LABORATORIES INC.
CEPHEID
CHARLES RIVER LABORATORIES
F. HOFFMANN-LA ROCHE LTD.
GENSCRIPT
GSK PLC
ILLUMINA INC.
JOHNSON & JOHNSON
ORASURE TECHNOLOGIES INC.
QIAGEN
REVVITY
THERMO FISHER SCIENTIFIC INC.
Emerging Startups/Market Disruptors

List of Tables

Summary Table: U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments, by Type, Through 2031
Table 1: U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments, by Type, Through 2031
Table 2: U.S. Market for Biodefense-Related Rapid Pathogen Detection Devices, by Testing Method, Through 2031
Table 3: U.S. Market for Biodefense-Related Rapid Pathogen Detection Devices, by Device Type, Through 2031
Table 4: Characteristics of Biosensors
Table 5: U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments, by Application, Through 2031
Table 6: U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments for Detection and Diagnosis, Through 2031
Table 7: U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments for Prevention, Through 2031
Table 8: U.S. Market for Biodefense-Related Rapid Pathogen Identification for Treatments, Through 2031
Table 9: U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments, by End User, Through 2031
Table 10: U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments for Government and Defense Agencies, Through 2031
Table 11: U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments for Hospitals, Through 2031
Table 12: U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments for Pharmaceutical and Biotechnology Companies, Through 2031
Table 13: U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments for Academic and Research Institutes, Through 2031
Table 14: Competitive Ranking of U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments, 2025
Table 15: Recent Developments in the U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments, 2024-2025
Table 16: Report Information Sources
Table 17: Abbreviations Used in This Report
Table 18: Abbott: Company Snapshot
Table 19: Abbott: Financial Performance, FY 2024 and 2025
Table 20: Abbott: Product Portfolio
Table 21: Abbott: News/Key Developments, 2024
Table 22: Agilent Technologies Inc.: Company Snapshot
Table 23: Agilent Technologies Inc.: Financial Performance, FY 2024 and 2025
Table 24: Agilent Technologies Inc.: Product Portfolio
Table 25: Agilent Technologies Inc.: News/Key Developments, 2024
Table 26: BD: Company Snapshot
Table 27: BD: Financial Performance, FY 2024 and 2025
Table 28: BD: Product Portfolio
Table 29: BD: News/Key Developments, 2025
Table 30: Biomerieux: Company Snapshot
Table 31: Biomerieux: Financial Performance, FY 2024 and 2025
Table 32: Biomerieux: Product Portfolio
Table 33: Biomerieux: News/Key Developments, 2024
Table 34: Bio-Rad Laboratories Inc.: Company Snapshot
Table 35: Bio-Rad Laboratories Inc.: Financial Performance, FY 2024 and 2025
Table 36: Bio-Rad Laboratories Inc.: Product Portfolio
Table 37: Bio-Rad Laboratories Inc.: News/Key Developments, 2025
Table 38: Cepheid: Company Snapshot
Table 39: Cepheid: Product Portfolio
Table 40: Cepheid: News/Key Developments, 2024-2025
Table 41: Charles River Laboratories: Company Snapshot
Table 42: Charles River Laboratories: Financial Performance, FY 2024 and 2025
Table 43: Charles River Laboratories: Product Portfolio
Table 44: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 45: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2024 and 2025
Table 46: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 47: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024-2025
Table 48: Genscript: Company Snapshot
Table 49: Genscript: Financial Performance, FY 2024 and 2025
Table 50: Genscript: Product Portfolio
Table 51: Genscript: News/Key Developments, 2024
Table 52: GSK plc: Company Snapshot
Table 53: GSK plc: Financial Performance, FY 2024 and 2025
Table 54: GSK plc: Product Portfolio
Table 55: GSK plc: News/Key Developments, 2024
Table 56: Illumina Inc.: Company Snapshot
Table 57: Illumina Inc.: Financial Performance, FY 2024 and 2025
Table 58: Illumina Inc.: Product Portfolio
Table 59: Illumina Inc.: News/Key Developments, 2025
Table 60: Johnson & Johnson: Company Snapshot
Table 61: Johnson & Johnson: Financial Performance, FY 2024 and 2025
Table 62: Johnson & Johnson: Product Portfolio
Table 63: Johnson & Johnson: News/Key Developments, 2024
Table 64: OraSure Technologies Inc.: Company Snapshot
Table 65: OraSure Technologies Inc.: Financial Performance, FY 2024 and 2025
Table 66: OraSure Technologies Inc.: Product Portfolio
Table 67: OraSure Technologies Inc.: News/Key Developments, 2024-2025
Table 68: Qiagen: Company Snapshot
Table 69: Qiagen: Financial Performance, FY 2024 and 2025
Table 70: Qiagen: Product Portfolio
Table 71: Qiagen: News/Key Developments, 2025
Table 72: Revvity: Company Snapshot
Table 73: Revvity: Financial Performance, FY 2024 and 2025
Table 74: Revvity: Product Portfolio
Table 75: Thermo Fisher Scientific Inc.: Company Snapshot
Table 76: Thermo Fisher Scientific Inc.: Financial Performance, FY 2024 and 2025
Table 77: Thermo Fisher Scientific Inc.: Product Portfolio
Table 78: List of a Few Emerging Startups

List of Figures

Summary Figure: U.S. Market Shares for Biodefense-Related Rapid Pathogen Identification and Treatments, by Type, 2025
Figure 1: Porter’s Five Forces Analysis: U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments
Figure 2: Market Dynamics of U.S. Biodefense-Related Rapid Pathogen Identification and Treatments
Figure 3: Emerging Technologies in U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments
Figure 4: U.S. Market Shares for Biodefense-Related Rapid Pathogen Identification and Treatments, by Type, 2025
Figure 5: U.S. Market Shares for Biodefense-Related Rapid Pathogen Detection Devices, by Testing Method, 2025
Figure 6: U.S. Market Shares for Biodefense-Related Rapid Pathogen Detection Devices, by Device Type, 2025
Figure 7: U.S. Market Shares for Biodefense-Related Rapid Pathogen Identification and Treatments, by Application, 2025
Figure 8: U.S. Market Shares for Biodefense-Related Rapid Pathogen Identification and Treatments, by End User, 2025
Figure 9: Abbott: Revenue Shares, by Business Unit, FY 2025
Figure 10: Abbott: Revenue Shares, by Country/Region, FY 2025
Figure 11: Agilent Technologies Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 12: Agilent Technologies Inc.: Revenue Shares, by Country/Region, FY 2025
Figure 13: BD: Revenue Shares, by Business Unit, FY 2025
Figure 14: BD: Revenue Shares, by Country/Region, FY 2025
Figure 15: Biomerieux: Revenue Shares, by Business Unit, FY 2025
Figure 16: Biomerieux: Revenue Shares, by Country/Region, FY 2025
Figure 17: Bio-Rad Laboratories Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 18: Bio-Rad Laboratories Inc.: Revenue Shares, by Country/Region, FY 2025
Figure 19: Charles River Laboratories: Revenue Shares, by Business Unit, FY 2025
Figure 20: Charles River Laboratories: Revenue Shares, by Country/Region, FY 2025
Figure 21: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2025
Figure 22: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2025
Figure 23: Genscript: Revenue Shares, by Business Unit, FY 2025
Figure 24: Genscript: Revenue Shares, by Country/Region, FY 2025
Figure 25: GSK plc: Revenue Shares, by Business Unit, FY 2025
Figure 26: GSK plc: Revenue Shares, by Region/Country, FY 2025
Figure 27: Illumina Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 28: Illumina Inc.: Revenue Shares, by Region, FY 2025
Figure 29: Johnson & Johnson: Revenue Shares, by Business Unit, FY 2025
Figure 30: Johnson & Johnson: Revenue Shares, by Country/Region, FY 2025
Figure 31: OraSure Technologies Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 32: OraSure Technologies Inc.: Revenue Shares, by Country/ Region, FY 2025
Figure 33: Qiagen: Revenue Shares, by Business Unit, FY 2025
Figure 34: Qiagen: Revenue Shares, by Country/Region, FY 2025
Figure 35: Revvity: Revenue Shares, by Business Unit, FY 2025
Figure 36: Revvity: Revenue Shares, by Country/Region, FY 2025
Figure 37: Thermo Fisher Scientific Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 38: Thermo Fisher Scientific Inc.: Revenue Shares, by Country/Region, FY 2025

Executive Summary

The U.S. market for biodefense-related rapid pathogen identification and treatments is expected to grow from $8.4 billion in 2026 and is projected to reach $12.1 billion by the end of 2031, at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2026 to 2031.

Companies Mentioned

ABBOTT
AGILENT TECHNOLOGIES INC.
BD
BIOMERIEUX
BIO-RAD LABORATORIES INC.
CEPHEID
CHARLES RIVER LABORATORIES
F. HOFFMANN-LA ROCHE LTD.
GENSCRIPT
GSK PLC
ILLUMINA INC.
JOHNSON & JOHNSON
ORASURE TECHNOLOGIES INC.
QIAGEN
REVVITY
THERMO FISHER SCIENTIFIC INC.

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4345EUR$4,650USD£3,630GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€5214EUR$5,580USD£4,356GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6257EUR$6,696USD£5,227GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€7508EUR$8,035USD£6,272GBP

The report includes:

Table of Contents

Executive Summary

Companies Mentioned

Related Topics

Related Reports

AI Impact on the U.S. Biodefense-Related Rapid Pathogen Identification and Treatments Market - Pulse Report

Biodefense Market - Global Forecast 2026-2032

Biodefense Market Report 2026

Biodefense Market by Technology, Product, Application, and Region - Global Forecast to 2030

Biodefense Market Insights, Competitive Landscape, and Market Forecast - 2033